07.11.16
Headquarters: Brentford, Middlesex, UK
twitter.com/GSK
www.gsk.com
Headcount: 101,255
Year Established: 2000
Revenues: $35,463 (-7%)
Net Income: $12,410 (+166%)
R&D: $5,277 (-7%)
TOP SELLING DRUGS
In 2015 GlaxoSmithKline (GSK) reported sales of $35.5 billion. The key event was the completion of its three-part deal with Novartis that was announced the year before. As a result of this transaction, GSK acquired Novartis’s global vaccines business, excluding influenza vaccines, for $5.25 billion. As part of the deal, GSK has also created a new leading consumer healthcare joint venture with Novartis in which GSK has majority control of 63.5%. Finally, GSK divested its oncology business to Novartis for $16 billion.
Following the Novartis deal, GSK further expanded its vaccines presence in the U.S. by establishing a new global center for vaccines research and development (R&D) in Rockville, MD. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D centers in Rixensart, Belgium and in Siena, Italy, a site GSK recently acquired as part of the Novartis deal.
The new U.S. vaccines R&D center will expand GSK’s efforts to discover and develop novel vaccines and it will consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia, PA and Cambridge, MA, into one centralized location. Key late stage development programs, as well as vaccine discovery and new platform technology development will be led from Rockville.
Also on the research front, GSK unveiled plans to become a key partner, with an investment of $25 million, in a pioneering new global fund for dementia research. The Dementia Discovery Fund, established by the UK government with initial commitments totaling $100 million, brings together leading pharmaceutical companies, the UK government and Alzheimer’s Research UK to address the rising threat posed by dementia by supporting research into future treatments. The fund aims to identify and nurture promising new avenues of research from around the world in the field of dementia and supports GSK’s commitment to explore novel, collaborative approaches in challenging areas of research.
In a unique public-private collaboration formed to create an HIV Cure center and a new company to bring together academic and pharmaceutical research scientists, The University of North Carolina at Chapel Hill and GSK, unveiled plans to create a dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. The HIV Cure center will be located on the UNC-Chapel Hill campus and will focus exclusively on finding a cure for HIV/AIDS. The new company, Qura Therapeutics, will handle the business side of the partnership, including intellectual property, commercialization, manufacturing and governance. Together, the HIV Cure center and Qura Therapeutics will serve as a catalyst for additional partners and public funding.
Through the new company, GSK will invest $4 million per year for five years to fund the initial HIV Cure center research plan, and a small research team from GSK will move to Chapel Hill to be co-located with UNC researchers. The University will provide world-class laboratory space on its medical campus for the HIV Cure center and the new company.
Further strengthening its HIV pipeline and outlook, GSK, through its global HIV business, ViiV Healthcare, reached two separate agreements with Bristol-Myers Squibb (BMS), to acquire its late-stage HIV R&D assets and to acquire its portfolio of preclinical and discovery stage HIV research assets.
Late stage assets, including fostemsavir (BMS-663068), an attachment inhibitor, currently in Phase III development for heavily treatment experienced patients that has received a breakthrough designation from the FDA and is expected to be filed for regulatory approval in 2018. The second late stage asset is a maturation inhibitor (BMS-955176), currently in Phase IIb development for both treatment-naive and treatment experienced patients. A back-up maturation inhibitor candidate (BMS-986173) is also included in the purchase.
Assets in preclinical and discovery phases of development include a novel biologic (BMS-986197) with a triple mechanism of action, a further maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor.
Also on the research front, during the year GSK teamed up with Merck to initiate a Phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumor(s) that have progressed after standard treatment.
In terms of acquisitions, in February GSK acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn. It acquired the remaining shares for $190 million to take full ownership of the company.
GlycoVaxyn has developed an innovative biological conjugation platform technology, which has the potential to play an important role in the development of new prophylactic and therapeutic vaccines for a range of bacterial diseases. This proprietary technology also has the potential to enable GSK to develop a simplified conjugate vaccine manufacturing process.
As part of the deal, GSK also acquired a small number of early stage vaccines in development against bacterial infections such as pneumonia, pseudomonas, staphylococcus aureus andShigellosis, supplementing the company’s existing vaccines pipeline.
Also of note in 2015, GSK started building its largest Indian tablet manufacturing pharmaceutical factory. When fully operational in 2017, the $140 million factory will make more than 8 billion tablets and 1 billion capsules a year in the areas of gastroenterology and anti-inflammatory medicines for the Indian market. The facility will be built on a 50-acre site in Vemgal, Karnataka. The facility will also include a warehouse, site infrastructure, employee welfare center and utilities to support the manufacturing and packing of the medicines.
During the year GSK also established a new global headquarters for Asia in Singapore. The eight-story, nearly 15,000 square meter facility will have capacity for up to 1,000 employees across GSK’s pharmaceuticals, vaccines and consumer healthcare businesses. Key leadership is already transitioning into the region with almost 150 global or regional roles moving to Singapore in the last year. Construction is expected to be complete by the end of 2016 and all employees will be situated at the new site during the second half of 2017.
twitter.com/GSK
www.gsk.com
Headcount: 101,255
Year Established: 2000
Revenues: $35,463 (-7%)
Net Income: $12,410 (+166%)
R&D: $5,277 (-7%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Seretide/Advair | asthma, COPD | $5,632 | -19% |
Infanrix, Pediarix | pediatric vaccine | $1,121 | -18% |
Epzicom/Kivexa | HIV | $1,068 | -16% |
Avodart | enlarged prostate | $1,006 | -24% |
Flixotide/Flovent | respiratory | $953 | -18% |
Ventolin | asthma | $949 | -13% |
Lamictal | anti-epileptic | $812 | -7% |
Augmentin | antibacterial | $808 | -14% |
In 2015 GlaxoSmithKline (GSK) reported sales of $35.5 billion. The key event was the completion of its three-part deal with Novartis that was announced the year before. As a result of this transaction, GSK acquired Novartis’s global vaccines business, excluding influenza vaccines, for $5.25 billion. As part of the deal, GSK has also created a new leading consumer healthcare joint venture with Novartis in which GSK has majority control of 63.5%. Finally, GSK divested its oncology business to Novartis for $16 billion.
Following the Novartis deal, GSK further expanded its vaccines presence in the U.S. by establishing a new global center for vaccines research and development (R&D) in Rockville, MD. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D centers in Rixensart, Belgium and in Siena, Italy, a site GSK recently acquired as part of the Novartis deal.
The new U.S. vaccines R&D center will expand GSK’s efforts to discover and develop novel vaccines and it will consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia, PA and Cambridge, MA, into one centralized location. Key late stage development programs, as well as vaccine discovery and new platform technology development will be led from Rockville.
Also on the research front, GSK unveiled plans to become a key partner, with an investment of $25 million, in a pioneering new global fund for dementia research. The Dementia Discovery Fund, established by the UK government with initial commitments totaling $100 million, brings together leading pharmaceutical companies, the UK government and Alzheimer’s Research UK to address the rising threat posed by dementia by supporting research into future treatments. The fund aims to identify and nurture promising new avenues of research from around the world in the field of dementia and supports GSK’s commitment to explore novel, collaborative approaches in challenging areas of research.
In a unique public-private collaboration formed to create an HIV Cure center and a new company to bring together academic and pharmaceutical research scientists, The University of North Carolina at Chapel Hill and GSK, unveiled plans to create a dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. The HIV Cure center will be located on the UNC-Chapel Hill campus and will focus exclusively on finding a cure for HIV/AIDS. The new company, Qura Therapeutics, will handle the business side of the partnership, including intellectual property, commercialization, manufacturing and governance. Together, the HIV Cure center and Qura Therapeutics will serve as a catalyst for additional partners and public funding.
Through the new company, GSK will invest $4 million per year for five years to fund the initial HIV Cure center research plan, and a small research team from GSK will move to Chapel Hill to be co-located with UNC researchers. The University will provide world-class laboratory space on its medical campus for the HIV Cure center and the new company.
Further strengthening its HIV pipeline and outlook, GSK, through its global HIV business, ViiV Healthcare, reached two separate agreements with Bristol-Myers Squibb (BMS), to acquire its late-stage HIV R&D assets and to acquire its portfolio of preclinical and discovery stage HIV research assets.
Late stage assets, including fostemsavir (BMS-663068), an attachment inhibitor, currently in Phase III development for heavily treatment experienced patients that has received a breakthrough designation from the FDA and is expected to be filed for regulatory approval in 2018. The second late stage asset is a maturation inhibitor (BMS-955176), currently in Phase IIb development for both treatment-naive and treatment experienced patients. A back-up maturation inhibitor candidate (BMS-986173) is also included in the purchase.
Assets in preclinical and discovery phases of development include a novel biologic (BMS-986197) with a triple mechanism of action, a further maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor.
Also on the research front, during the year GSK teamed up with Merck to initiate a Phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumor(s) that have progressed after standard treatment.
In terms of acquisitions, in February GSK acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn. It acquired the remaining shares for $190 million to take full ownership of the company.
GlycoVaxyn has developed an innovative biological conjugation platform technology, which has the potential to play an important role in the development of new prophylactic and therapeutic vaccines for a range of bacterial diseases. This proprietary technology also has the potential to enable GSK to develop a simplified conjugate vaccine manufacturing process.
As part of the deal, GSK also acquired a small number of early stage vaccines in development against bacterial infections such as pneumonia, pseudomonas, staphylococcus aureus andShigellosis, supplementing the company’s existing vaccines pipeline.
Also of note in 2015, GSK started building its largest Indian tablet manufacturing pharmaceutical factory. When fully operational in 2017, the $140 million factory will make more than 8 billion tablets and 1 billion capsules a year in the areas of gastroenterology and anti-inflammatory medicines for the Indian market. The facility will be built on a 50-acre site in Vemgal, Karnataka. The facility will also include a warehouse, site infrastructure, employee welfare center and utilities to support the manufacturing and packing of the medicines.
During the year GSK also established a new global headquarters for Asia in Singapore. The eight-story, nearly 15,000 square meter facility will have capacity for up to 1,000 employees across GSK’s pharmaceuticals, vaccines and consumer healthcare businesses. Key leadership is already transitioning into the region with almost 150 global or regional roles moving to Singapore in the last year. Construction is expected to be complete by the end of 2016 and all employees will be situated at the new site during the second half of 2017.